Oncologic Drugs Advisory Committee (ODAC) has voted against the benefit/risk profile of GSK’s Blenrep (belantamab mafodotin) ...

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

US and European stock markets stalled or trimmed gains on Friday after a bullish week buoyed by US data and upbeat company ...

GSK plc GSK announced that the FDA’s Oncologic Drugs Advisory Committee (ODAC) has voted against the overall benefit/risk profile of the Blenrep (belantamab mafodotin-blmf) combination therapy at the ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

Upbeat company earnings and healthy US data buoyed stock markets on Friday, pushing ongoing concerns about President Donald ...

European and Asian stocks markets closed out the week broadly higher Friday following Wall Street's latest record highs ...

Jaguar Land Rover to cut jobs, Marks & Spencer give staff extra discount - Latest stock markets updates, business and money ...

Euro US Dollar, British Pound US Dollar, US Dollar Japanese Yen, FTSE 100. Read 's Market Analysis on Investing.com ...

Find insight on GSK, Novartis , Sarepta Therapeutics and more in the latest Market Talks covering Health Care.

The panel expressed concerns about the proposed doses of Blenrep (belantamab mafodotin) in GSK's marketing application, ...

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...